Document:

Exhibit 10.4

 Exhibit C 
  

REGISTRATION RIGHTS AGREEMENT 
  
 This Registration Rights Agreement (“Agreement”) is entered into as of April 15, 2004, between Star Scientific, Inc., a Delaware
corporation with offices at 801 Liberty Way, Chester, Virginia 23836 (the “Company”) and the Purchasers set forth on the signature page hereto (the “Purchasers”). 
  
 W I T N E S S E
T H: 
  
 WHEREAS, pursuant to the Securities
Purchase Agreement, dated on or about the date hereof, by and between the Company and the Purchasers (the “Purchase Agreement”), the Company has agreed to sell and issue to the Purchasers, and the Purchasers have agreed to purchase
from the Company, 142,857 shares (the “Common Shares”) of the common stock, par value $0.0001 per share (the “Common Stock”) of the Company subject to the terms and conditions set forth therein; and 
  
 WHEREAS, pursuant to the Purchase Agreement, upon the effectiveness of the
registration of the Common Shares pursuant to this Agreement and for a period of 30 days thereafter, the Purchasers shall have the option (the “Option”) to purchase an additional 134,048 shares (the “Option Shares”
and together with the Common Shares, the “Shares”) of Common Stock on the same terms and conditions set forth in the Purchase Agreement; 
  
 NOW, THEREFORE, in consideration of the mutual promises, representations, warranties, covenants and conditions set forth in the Purchase Agreements and
this Agreement, the Company and each Purchaser agree as follows: 
  
 1. Certain Definitions. Capitalized terms used herein and not otherwise defined shall have the meaning ascribed thereto in the Purchase Agreements. As used in this Agreement, the following terms shall have the following respective
meanings: 
  
 “Closing” and “Closing
Date” shall mean the Closing and Closing Date with respect to the purchase of the Common Shares. 
  
 “Commission” or “SEC” shall mean the Securities and Exchange Commission or any other federal agency at the time
administering the Securities Act. 
  
 “Exercise
Period” shall have the meaning ascribed to it in the Purchase Agreement. 
  
 “Holder” and “Holders” shall include the Purchasers and any transferee or transferees of Registrable Securities which have not been sold to the public to whom the registration rights
conferred by this Agreement have been transferred in compliance with this Agreement and the Purchase Agreement. 
  
 “1934 Act” shall mean the Securities Exchange Act of 1934, as amended. 
  
 The terms “register,” “registered” and “registration” shall refer to a
registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the declaration or ordering of the effectiveness of such registration statement.

			
	 Star Scientific, Inc.
	 	Page 2

  

 “Registrable Securities” shall mean: (i) the Common Shares and the Options Shares
(without regard to any limitations on beneficial ownership contained in the Purchase Agreement) issued or issuable to each Holder upon exercise of the Option; (ii) securities issued or issuable upon any stock split, stock dividend, recapitalization
or similar event with respect to the foregoing; and (iii) any other security issued as a dividend or other distribution with respect to, in exchange for or in replacement of the securities referred to in the preceding clauses, except that any such
Shares or other securities shall cease to be Registrable Securities when (x) they have been sold to the public or (y) they may be sold by the Holder thereof under Rule 144(k). 
  
 “Registration Expenses” shall mean all expenses to be incurred by the Company in connection with each
Holder’s registration rights under this Agreement (such amount not to exceed $5,000 in the aggregate), including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel for the Company, and
blue sky fees and expenses, reasonable fees and disbursements of counsel to Holders (using a single counsel selected by a majority in interest of the Holders) for a review of the Registration Statement and related documents, and the expense of any
special audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company, which shall be paid in any event by the Company). 
  
 “Registration Statement” shall have the meaning set forth in Section 2(a) herein. 
  
 “Regulation D” shall mean Regulation D as promulgated
pursuant to the Securities Act, and as subsequently amended. 
  
 “Securities Act” or “Act” shall mean the Securities Act of 1933, as amended. 
  
 “Selling Expenses” shall mean all underwriting discounts, selling commissions and transfer taxes applicable to the sale of Registrable
Securities and all fees and disbursements of counsel for Holders not included within “Registration Expenses”. 
  
 2. Registration Requirements. The Company shall use its best efforts to effect the registration of the resale of the Registrable Securities
(including, without limitation, the execution of an undertaking to file post-effective amendments, appropriate qualification under applicable blue sky or other state securities laws and appropriate compliance with applicable regulations issued under
the Securities Act) as would permit or facilitate the resale of all the Registrable Securities in the manner (including manner of sale) and in all states reasonably requested by the Holder. Such best efforts by the Company shall include, without
limitation, the following: 
  
 (a) The Company shall, as
expeditiously as possible after the Closing Date: 
  
 (i) But in any event within 24 days of the Closing (the “Filing Deadline”), prepare and file a registration statement with the Commission pursuant to Rule 415 under the Securities Act on Form S-3 under the Securities Act
(or in the event that the Company is ineligible to use such form, such other 

			
	 Star Scientific, Inc.
	 	Page 3

  

 form as the Company is eligible to use under the Securities Act provided that such other form shall be
converted into an S-3 as soon as Form S-3 becomes available to the Company) covering resales by the Holders as selling stockholders (not underwriters) of the Registrable Securities and, to the extent practicable, no other securities other than
shares of Common Stock issued pursuant to (A) the Securities Purchase Agreement dated as of March 25, 2004, between the Company and Manchester Securities Corp., and the shares of Common Stock issuable upon conversion of the convertible debentures
and exercise of the warrants issued in connection therewith, (B) the Restated Non-Circumvention and Finder’s Fee Agreement dated March 24, 2004, including shares issued upon exercise of warrants issued in connection therewith, and (C)
securities purchase agreements entered into by the Company and purchasers substantially contemporaneously with this Agreement (including pursuant to any option to purchase Common Stock contained therein) (the “Registration
Statement”), which Registration Statement, to the extent allowable under the Securities Act and the rules promulgated thereunder (including Rule 416). The number of shares of Common Stock initially included in such Registration Statement
shall be no less than (x) 100% of the Common Shares acquired by Purchasers pursuant to the Purchase Agreement, and (y) to the extent permitted by the forms, rules and regulations of the Commission, 100% of the Option Shares issuable upon exercise of
the Option in full pursuant to the Purchase Agreement. Nothing in the preceding sentence will limit the Company’s obligations to reserve shares of Common Stock pursuant to Section 3.3 of the Purchase Agreement. Thereafter the Company shall use
its best efforts to cause such Registration Statement and other filings to be declared effective as soon as possible, and in any event prior to 69 days (or, if the SEC elects to review the Registration Statement, 129 days) following the Closing Date
(the “Effectiveness Deadline”). Without limiting the foregoing, the Company will promptly respond to all SEC comments, inquiries and requests, and shall request acceleration of effectiveness at the earliest possible date. The
Company shall provide the Holders reasonable opportunity to review any such Registration Statement or amendment or supplement thereto prior to filing. 
  
 (ii) Prepare and file with the SEC such amendments and supplements to such Registration Statement and the prospectus used in connection
with such Registration Statement as may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered by such Registration Statement and notify the Holders of the filing and effectiveness of such
Registration Statement and any amendments or supplements. 
  
 (iii) Furnish to each Holder such numbers of copies of a current prospectus conforming with the requirements of the Act, copies of the Registration Statement, any amendment or supplement thereto and any documents
incorporated by reference therein and such other documents as such Holder may reasonably require in order to facilitate the disposition of Registrable Securities owned by such Holder. 

			
	 Star Scientific, Inc.
	 	Page 4

  

 (iv) Register and qualify the securities covered by such Registration Statement under the
securities or “Blue Sky” laws of all domestic jurisdictions, to the extent required; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent
to service of process in any such states or jurisdictions. 
  
 (v) Notify each Holder immediately of the happening of any event (but not the substance or details of any such events unless specifically requested by a Holder) as a result of which the prospectus (including any
supplements thereto or thereof) included in such Registration Statement, as then in effect, includes an untrue statement of material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not
misleading in light of the circumstances then existing, and use its best efforts to promptly update and/or correct such prospectus. 
  
 (vi) Notify each Holder immediately of the issuance by the Commission or any state securities commission or agency of any stop order
suspending the effectiveness of the Registration Statement or the threat or initiation of any proceedings for that purpose. The Company shall use its best efforts to prevent the issuance of any stop order and, if any stop order is issued, to obtain
the lifting thereof at the earliest possible time. 
  
 (vii) Permit counsel to the Holders to review the Registration Statement and all amendments and supplements thereto within a reasonable period of time (but not less than two (2) full Trading Days prior to each filing and will not request
acceleration of the Registration Statement without prior notice to such counsel. 
  
 (viii) List the Registrable Securities covered by such Registration Statement with all securities exchange(s) and/or markets on which the
Common Stock is then listed and prepare and file any required filings with the Principal Market. 
  
 (b) Set forth below in this Section 2(b) are (I) events that may arise that the Purchasers consider will interfere with the full enjoyment of their
rights under this Agreement and the Purchase Agreement (the “Interfering Events”), and (II) certain remedies applicable in each of these events. 
  
 Paragraphs (i) through (iii) of this Section 2(b) describe the Interfering Events, provide a remedy to the Purchasers if an
Interfering Event occurs. 
  
 Paragraph (iv) provides, inter alia,
that the each Purchaser has the right to specific performance. 
  
 The preceding paragraphs in this Section 2(b) are meant to serve only as an introduction to this Section 2(b), are for convenience only, and are not to be considered in applying, construing or interpreting this Section 2(b). 

			
	 Star Scientific, Inc.
	 	Page 5

  

 (i) Delay in Effectiveness of Registration Statement. 
  
 In the event that such Registration Statement has not been declared
effective by: (x) the Effectiveness Deadline if the SEC does not elect to review the Registration Statement or (y) within 129 days of the Closing Date, if the SEC elects to review the Registration Statement, or the Company at any time fails to issue
unlegended Registrable Securities to the extent required by Article V of the Purchase Agreement, then the Company shall pay each Holder (other than (i) in the case of a Registration Statement not declared effective, a Holder of Registrable
Securities that the Company could exclude from registration in accordance with Section 9 and (ii) in the case of a failure to issue unlegended certificates in accordance with the Purchase Agreement, a Holder that is not a party to, including as a
permitted assignee bound to, the Purchase Agreement) a Monthly Delay Payment (as defined below) with respect to each successive 30-day period (or portion thereof appropriately prorated) thereafter that effectiveness of the Registration Statement is
delayed or failure to issue such unlegended Registrable Securities persists. 
  
 (B) Subject to subsection (C)(II) below, as used in this Agreement, a “Monthly Delay Payment” shall be a cash payment equal to 1% of the amount equal to (x) the Per Share Purchase Price (as defined in
the Purchase Agreement) multiplied by (y) the sum of the number of Shares that are Registrable Securities and held by the applicable Holder. Payment of the Monthly Delay Payments shall be due and payable from the Company to such Holder on the later
of (I) the end of the applicable 30-day period or portion thereof and (II) 5 business days after demand therefor. 
  
 (C) Notwithstanding the foregoing, (I) there shall be excluded from the calculation of the number of days that the Registration Statement
has not been declared effective the delays which are solely attributable to delays in a Purchaser providing information required for the Registration Statement and (II) the aggregate amount of Monthly Delay Payments payable to a Purchaser pursuant
to this Agreement shall not exceed ten (10) times the amount of Monthly Delay Payment calculated for such Purchaser pursuant to subsection (B) above. 
  
 (ii) Blackout Periods. In the event the Registration has become effective and, afterwards, any Holder’s ability to sell
Registrable Securities under the Registration Statement is suspended for more than (i) 30 days in any 90-day period or (ii) 60 days in any calendar year (“Suspension Grace Period”), including without limitation by reason of any
suspension or stop order with respect to the Registration Statement or the fact that an event has occurred as a result of which the prospectus (including any supplements thereto) included in such Registration Statement then in effect includes an
untrue statement of material fact or omits to state a material fact required to be stated therein or 

			
	 Star Scientific, Inc.
	 	Page 6

  

 necessary to make the statements therein not misleading in light of the circumstances then existing (a
“Blackout”), then the Company shall provide to each Holder a Monthly Delay Payment for each 30-day period or portion thereof (appropriately prorated) from and after the expiration of the Suspension Grace Period, on the terms set
forth in Section 2(b)(i)(B) above. 
  
 (iii)
No Listing; Premium Price Redemption for Delisting of Class of Shares. 
  
 (A) In the event that the Company fails, refuses or for any other reason is unable to cause the Registrable Securities covered by the
Registration Statement to be listed with the Principal Market or one of the other Approved Markets (as defined in the Purchase Agreement) at all times during the period (“Listing Period”) from the date (“Effectiveness
Commencement Date”) which is the earlier of the effectiveness of the Registration Statement and the 69th
day following the Closing Date (or the 129th day if the SEC elects to review the Registration Statement) until such
time as the registration period specified in Section 5 terminates, then the Company shall provide to each Holder a Monthly Delay Payment, for each 30 day period or portion thereof (appropriately prorated) during which such listing is not in effect.

  
 (B) In the event that shares of Common Stock
of the Company are not listed on any of the Approved Markets at all times following the Closing Date, or are otherwise suspended from trading and remain unlisted or suspended for 3 consecutive days, then the Company shall provide to each Holder a
Monthly Delay Payment for each 30-day period or portion thereof (appropriately prorated) during which such listing is not in effect. 
  
 (C) Notwithstanding the above in this Section 2(b)(iii), the aggregate amount payable to a Purchaser under this Section 2(b)(iii) shall
not exceed the product of multiplying the Monthly Delay Payment times nine (9) 
  
 (iv) Cumulative Remedies. The Monthly Delay Payments provided for above are in addition to and not in lieu or limitation of any
other rights the Holders may have at law, in equity or under the terms of the Purchase Agreement and this Agreement, including without limitation, the right to monetary contract damages and specific performance. Each Holder shall be entitled to
specific performance of any and all obligations of the Company in connection with the registration rights of the Holders hereunder. 
  
 (c) If the Holder(s) intend to distribute the Registrable Securities by means of an underwriting, the Holder(s) shall so advise the Company. Any such
underwriting may only be administered by nationally or regionally recognized investment bankers reasonably satisfactory to the Company. 

			
	 Star Scientific, Inc.
	 	Page 7

  

 (d) The Company shall enter into such customary agreements for secondary offerings (including a
customary underwriting agreement with the underwriter or underwriters, if any) and take all such other reasonable actions reasonably requested by the Holders in connection with any underwritten offering or when the SEC has required that the Holders
be identified as underwriters in the Registration Statement in order to expedite or facilitate the disposition of such Registrable Securities and in such connection: 
  
 (i) make such representations and warranties to the Holders and the underwriter or underwriters, if any, in
form, substance and scope as are customarily made by issuers to underwriters in secondary offerings; 
  
 (ii) cause to be delivered to the sellers of Registrable Securities and the underwriter or underwriters, if any, opinions of independent
counsel to the Company, on and dated as of the effective day (or in the case of an underwritten offering, dated the date of delivery of any Registrable Securities sold pursuant thereto) of the Registration Statement, and within ninety (90) days
following the end of each fiscal year thereafter, which counsel and opinions (in form, scope and substance) shall be reasonably satisfactory to the Holders and the underwriter(s), if any, and their counsel and covering such matters that are
customarily given to underwriters in underwritten offerings, addressed to the Holders and each underwriter, if any; 
  
 (iii) cause to be delivered, immediately prior to the effectiveness of the Registration Statement (and, in the case of an underwritten
offering, at the time of delivery of any Registrable Securities sold pursuant thereto), and at the beginning of each fiscal year following a year during which the Company’s independent certified public accountants shall have reviewed any of the
Company’s books or records, a “comfort” letter from the Company’s independent certified public accountants addressed to each underwriter (including the Holders, if the SEC has required them to be identified as underwriters in the
Registration Statement), if any, to the extent requested by such underwriters, stating that such accountants are independent public accountants within the meaning of the Securities Act and the applicable published rules and regulations thereunder,
and otherwise in customary form and covering such financial and accounting matters as are customarily covered by letters of the independent certified public accountants delivered in connection with secondary offerings; such accountants shall have
undertaken in each such letter to update the same during each such fiscal year in which such books or records are being reviewed so that each such letter shall remain current, correct and complete throughout such fiscal year; and each such letter
and update thereof, if any, shall be reasonably satisfactory to such underwriters; 
  
 (iv) if an underwriting agreement is entered into, the same shall include customary indemnification and contribution provisions to and
from the underwriters and procedures for secondary underwritten offerings; and 

			
	 Star Scientific, Inc.
	 	Page 8

  

 (v) deliver such documents and certificates as may be reasonably requested by the Holders
of the Registrable Securities being sold or the managing underwriter or underwriters, if any, to evidence compliance with clause (i) above and with any customary conditions contained in the underwriting agreement, if any. 
  
 (e) The Company shall make available for inspection by the Holders,
representative(s) of all the Holders together, any underwriter participating in any disposition pursuant to a Registration Statement, and any attorney or accountant retained by any Holder or underwriter, all financial and other records customary for
purposes of the Holders’ due diligence examination of the Company and review of any Registration Statement, all SEC Documents (as defined in the Purchase Agreement) filed subsequent to the Closing, pertinent corporate documents and properties
of the Company, and cause the Company’s officers, directors and employees to supply all information reasonably requested by any such representative, underwriter, attorney or accountant in connection with such Registration Statement, provided
that such parties agree to keep such information confidential. Notwithstanding the foregoing, the foregoing right shall not extend to any Holder (i) who is not a financial investor or entity or (ii) who, itself or through any affiliate, has any
strategic business interest that would reasonably be expected to be in conflict with any business of the Company or its subsidiaries. 
  
 (f) Subject to Section 2(b) above and to clause (i) below, the Company may suspend the use of any prospectus used in connection with the Registration
Statement only in the event, and for such period of time as, (i) such a suspension is required by the rules and regulations of the Commission or (ii) it is determined in good faith by the Board of Directors of the Company that because of valid
business reasons (not including the avoidance of the Company’s obligations hereunder), it is in the best interests of the Company to suspend such use, and prior to suspending such use in accordance with this clause (ii) the Company provides the
Holders with written notice of such suspension, which notice need not specify the nature of the event giving rise to such suspension. The Company will use reasonable best efforts to cause such suspension to terminate at the earliest possible date.
This provision shall not affect the right of Holders to receive Monthly Delay Payments pursuant to Section 2(b) above. 
  
 (g) The Company shall file a Registration Statement with respect to any newly authorized and/or reserved Registrable Securities consisting of Common
Shares or Option Shares described in clause (i) of the definition of Registrable Securities within five (5) business days of any stockholders meeting authorizing same and shall use its best efforts to cause such Registration Statement to become
effective within sixty (60) days of such stockholders meeting. If the Holders become entitled, pursuant to an event described in clause (ii) and (iii) of the definition of Registrable Securities, to receive any securities in respect of Registrable
Securities that were already included in a Registration Statement, subsequent to the date such Registration Statement is declared effective, and the Company is unable under the securities laws to add such securities to the then effective
Registration Statement, the Company shall promptly file, in accordance with the procedures set forth herein, an additional Registration Statement with respect to such newly Registrable Securities. The Company shall use its best efforts to (i) cause
any such additional Registration Statement, when filed, to become effective under the Securities Act, and (ii) keep such additional Registration Statement effective during the period described in Section 5 below and cause such Registration Statement
to become effective within 90 days of 

			
	 Star Scientific, Inc.
	 	Page 9

  

 that date that the need to file the Registration Statement arose. All of the registration rights and remedies under this
Agreement shall apply to the registration of the resale of such newly reserved shares and such new Registrable Securities, including without limitation the provisions providing for default payments contained herein. 
  
 (h) The Company shall prepare and file with the SEC such amendments
(including post-effective amendments) and supplements to a Registration Statement and the prospectus used in connection with such Registration Statement, which prospectus is to be filed pursuant to Rule 424 promulgated under the Securities Act, as
may be necessary to keep such Registration Statement effective at all times during the Registration Period (as defined below), and, during such period, comply with the provisions of the Securities Act with respect to the disposition of all
Registrable Securities of the Company covered by such Registration Statement. In the case of amendments and supplements to a Registration Statement which are required to be filed pursuant to this Agreement (including pursuant to this Section 3(b))
by reason of the Company filing a report on Form 10-K, Form 10-Q or Form 8-K or any analogous report under the 1934 Act, the Company shall have incorporated such report by reference into such Registration Statement, if applicable, or shall file such
amendments or supplements with the SEC on the same day on which the 1934 Act report is filed which created the requirement for the Company to amend or supplement such Registration Statement. 
  
 (i) Each Holder agrees by its acquisition of the Registrable Securities
that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Sections 2(a)(v) or 2(a)(vi), such Holder will forthwith discontinue disposition of such Registrable Securities under the Registration Statement
until such Holder’s receipt of the copies of the supplemented Prospectus and/or amended Registration Statement contemplated by Section 3(l), or until it is advised in writing (the “Advice”) by the Company that the use of the
applicable Prospectus may be resumed, and, in either case, has received copies of any additional or supplemental filings that are incorporated or deemed to be incorporated by reference in such Prospectus or Registration Statement. The Company may
provide appropriate stop orders to enforce the provisions of this paragraph. 
  
 (j) If requested by a Holder, the Company shall (i) as soon as practicable incorporate in a prospectus supplement or post-effective amendment such information as a Holder reasonably requests to be included therein
relating to the sale and distribution of Registrable Securities, including, without limitation, information with respect to the number of Registrable Securities being offered or sold, the purchase price being paid therefor and any other terms of the
offering of the Registrable Securities to be sold in such offering; (ii) as soon as practicable make all required filings of such prospectus supplement or post-effective amendment after being notified of the matters to be incorporated in such
prospectus supplement or post-effective amendment; and (iii) as soon as practicable, supplement or make amendments to any Registration Statement if reasonably requested by a Holder holding any Registrable Securities. 

			
	 Star Scientific, Inc.
	 	Page 10

  

 (k) If a Purchaser exercises the Option and the Company issues Option Shares, and the Option Shares were
not registered pursuant to Section 2(a) above, then all of the provisions of this Registration Rights Agreement shall apply to such Option Shares, mutatis mutandis, as if they were Common Shares registered pursuant to Section 2(a) above, with
the following changes: 
  
 (i) References
to the Closing and Closing Date shall refer to the last day of the Exercise Period (the “Option Closing Date”). 
  
 (ii) References to the Effectiveness Deadline shall refer to 90 days from the Option Closing Date if there is no SEC review, and 150 days
from the Option Closing Date if there is. 
  
 (iii) References to the Filing Deadline for the registration statement for the Option Shares shall refer to forty-five (45) days from the Option Closing Date. 
  
 (iv) References in this Agreement to Common Shares shall be deemed to refer to Option Shares. 
  
 (l) The Company agrees that until the Registration Statement filed pursuant
to Section 2(a) is declared effective by the SEC, it will not file any other registration statements with the SEC. 
  
 3. Expenses of Registration. All Registration Expenses in connection with any registration, qualification or compliance with registration pursuant
to this Agreement shall be borne by the Company, and all Selling Expenses of a Holder shall be borne by such Holder. 
  
 4. Registration on Form S-3. The Company shall use its best efforts to remain qualified for registration on Form S-3 or any comparable or successor
form or forms, or in the event that the Company is ineligible to use such form, such form as the Company is eligible to use under the Securities Act, provided that if such other form is used, the Company shall convert such other form to a Form S-3
as soon as the Company becomes so eligible, provided that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement or Form S-3 covering the Registrable Securities has been
declared effective by the SEC. 
  
 5. Registration Period.
In the case of the registration effected by the Company pursuant to this Agreement, the Company shall keep such registration effective until the earlier of (a) the date on which all the Holders have completed the sales or distribution described in
the Registration Statement relating thereto or, (b) until such Registrable Securities may be sold by the Holders under Rule 144(k) (provided that the Company’s transfer agent has accepted an instruction from the Company to such effect) (the
“Registration Period”). Subject to Section 8 below, this Agreement shall be terminated automatically without further action by any party hereto upon the expiration of the Registration Period. 
  
 6. Indemnification. 
  
 (a) Company Indemnity. The Company will indemnify and hold harmless
each Holder, each of its officers, directors, agents and partners, and each person controlling each of the foregoing, within the meaning of Section 15 of the Securities Act and the 

			
	 Star Scientific, Inc.
	 	Page 11

  

 rules and regulations thereunder with respect to which registration, qualification or compliance has been effected
pursuant to this Agreement, and each underwriter, if any, and each person who controls, within the meaning of Section 15 of the Securities Act and the rules and regulations thereunder, any underwriter, against all claims, losses, damages and
liabilities (or actions in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus, offering circular or other document (including any related registration
statement, notification or the like) incident to any such registration, qualification or compliance, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements
therein not misleading in light of the circumstances under which they were made, or any violation by the Company of the Securities Act or any state securities law or in either case, any rule or regulation thereunder applicable to the Company and
relating to action or inaction required of the Company in connection with any such registration, qualification or compliance, and will reimburse each Holder, each of its officers, directors, agents and partners, and each person controlling each of
the foregoing, each such underwriter and each person who controls any such underwriter, for any legal and any other expenses reasonably incurred in connection with investigating and defending any such claim, loss, damage, liability or action,
provided that the Company will not be liable in any such case to a Holder to the extent that any such claim, loss, damage, liability or expense arises out of or is based (i) on any untrue statement or omission based upon written information
furnished to the Company by such Holder or the underwriter (if any) therefor and stated to be specifically for use therein or (ii) the failure of a Holder to deliver at or prior to the written confirmation of sale, the most recent prospectus, as
amended or supplemented. The indemnity agreement contained in this Section 6(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company
(which consent will not be unreasonably withheld). 
  
 (b)
Holder Indemnity. Each Holder will, severally and not jointly, if Registrable Securities held by it are included in the securities as to which such registration, qualification or compliance is being effected, indemnify and hold harmless the
Company, each of its directors, officers, agents and partners, and each underwriter, if any, of the Company’s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of
Section 15 of the Securities Act and the rules and regulations thereunder, each other Holder (if any), and each of their officers, directors and partners, and each person controlling such other Holder(s) against all claims, losses, damages and
liabilities (or actions in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any such registration statement, prospectus, offering circular or other document, or any
omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statement therein not misleading in light of the circumstances under which they were made, and will reimburse the Company and such
other Holder(s) and their directors, officers and partners, underwriters or control persons for any legal or any other expenses reasonably incurred in connection with investigating and defending any such claim, loss, damage, liability or action, in
each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance upon and
in conformity with written information furnished to the Company by such Holder and stated to be specifically for use therein, and provided that the maximum amount for which such Holder shall be liable under this indemnity shall not 

			
	 Star Scientific, Inc.
	 	Page 12

  

 exceed the net proceeds received by such Holder from the sale of the Registrable Securities pursuant to the registration
statement in question. The indemnity agreement contained in this Section 6(b) shall not apply to amounts paid in settlement of any such claims, losses, damages or liabilities if such settlement is effected without the consent of such Holder (which
consent shall not be unreasonably withheld). 
  
 (c)
Procedure. Each party entitled to indemnification under this Section 6 (the “Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after
such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim in any litigation resulting therefrom, provided that counsel for the
Indemnifying Party, who shall conduct the defense of such claim or any litigation resulting therefrom, shall be approved by the Indemnified Party (whose approval shall not be unreasonably withheld), and the Indemnified Party may participate in such
defense at its own expense, and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 6 except to the extent that the Indemnifying
Party is materially and adversely affected by such failure to provide notice. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter
into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. Each Indemnified Party shall
furnish such non-privileged information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be reasonably required in connection with the defense of such claim and litigation resulting
therefrom. 
  
 7. Contribution. If the indemnification
provided for in Section 6 herein is unavailable to the Indemnified Parties in respect of any losses, claims, damages or liabilities referred to herein (other than by reason of the exceptions provided therein), then each such Indemnifying Party, in
lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such losses, claims, damages or liabilities as between the Company on the one hand and any Holder on the other, in
such proportion as is appropriate to reflect the relative fault of the Company and of such Holder in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative fault of the Company on the one hand and of any Holder on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged
omission to state a material fact relates to information supplied by the Company or by such Holder. 
  
 In no event shall the obligation of any Indemnifying Party to contribute under this Section 7 exceed the amount that such Indemnifying Party would have
been obligated to pay by way of indemnification if the indemnification provided for under Section 6(a) or 6(b) hereof had been available under the circumstances. 
  
 The Company and the Holders agree that it would not be just and equitable if contribution pursuant to this Section 7 were
determined by pro rata allocation (even if the Holders or the underwriters were treated as one entity for such purpose) or by any other method 

			
	 Star Scientific, Inc.
	 	Page 13

  

 of allocation which does not take account of the equitable considerations referred to in the immediately preceding
paragraphs. The amount paid or payable by an Indemnified Party as a result of the losses, claims, damages and liabilities referred to in the immediately preceding paragraphs shall be deemed to include, subject to the limitations set forth above, any
legal or other expenses reasonably incurred by such Indemnified Party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this section, no Holder or underwriter shall be required to contribute
any amount in excess of the amount by which (i) in the case of any Holder, the net proceeds received by such Holder from the sale of Registrable Securities pursuant to the registration statement in question or (ii) in the case of an underwriter, the
total price at which the Registrable Securities purchased by it and distributed to the public were offered to the public exceeds, in any such case, the amount of any damages that such Holder or underwriter has otherwise been required to pay by
reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was
not guilty of such fraudulent misrepresentation. 
  
 8.
Survival. The indemnity and contribution agreements contained in Sections 6 and 7 and the representations and warranties of the Company referred to in Section 2(d)(i) shall remain operative and in full force and effect regardless of (i) any
termination of this Agreement or the Purchase Agreement or any underwriting agreement, (ii) any investigation made by or on behalf of any Indemnified Party or by or on behalf of the Company, and (iii) the consummation of the sale or successive
resales of the Registrable Securities. 
  
 9. Information by
Holders. Each Holder shall promptly furnish to the Company such information regarding such Holder and the distribution and/or sale proposed by such Holder as the Company may from time to time reasonably request in writing in connection with any
registration, qualification or compliance referred to in this Agreement, and the Company may exclude from such registration the Registrable Securities of any Holder who unreasonably fails to furnish such information within a reasonable time after
receiving such request. The intended method or methods of disposition and/or sale (Plan of Distribution) of such securities as so provided by such Purchaser shall be included without alteration in the Registration Statement covering the Registrable
Securities and shall not be changed without written consent of such Holder. Each Holder agrees that, other than ordinary course brokerage arrangements, in the event it enters into any arrangement with a broker dealer for the sale of any Registrable
Securities through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, such Holder shall promptly deliver to the Company in writing all applicable information required in order for
the Company to be able to timely file a supplement to the Prospectus pursuant to Rule 424(b) under the Securities Act, to the extent that such supplement is legally required. Such information shall include a description of (i) the name of such
Holder and of the participating broker dealer(s), (ii) the number of Registrable Securities involved, (iii) the price at which such Registrable Securities were or are to be sold, and (iv) the commissions paid or to be paid or discounts or
concessions allowed or to be allowed to such broker dealer(s), where applicable. 
  
 10. Replacement Certificates. The certificate(s) representing the Registrable Securities held by any Purchaser (or then Holder) may be exchanged by such Purchaser (or such Holder) at any time and from time to
time for certificates with different denominations representing an equal aggregate number of Registerable Securities, as reasonably requested by such Purchaser 

			
	 Star Scientific, Inc.
	 	Page 14

  

 (or such Holder) upon surrendering the same. No service charge will be made for such registration or exchange. Upon
receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of any certificates representing a Registrable Security and, in the case of loss, theft or destruction, of indemnity reasonably
satisfactory to it, or upon surrender and cancellation of such certificate if mutilated, the Company will make and deliver a new certificate of like tenor and dated as of such cancellation at no charge to the holder. 
  
 11. Transfer or Assignment. Except as otherwise provided herein, this
Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The rights granted to the Purchasers by the Company under this Agreement to cause the Company to register Registrable Securities may
be transferred or assigned (in whole or in part) to a permitted transferee or assignee of Registrable Securities, and all other rights granted to the Purchasers by the Company hereunder may be transferred or assigned to any permitted transferee or
assignee of Registrable Securities; provided in each case that the Company must be given written notice by such Purchaser at the time of or within a reasonable time after said transfer or assignment, stating the name and address of said transferee
or assignee and identifying the securities with respect to which such registration rights are being transferred or assigned; and provided further that the transferee or assignee of such rights agrees in writing to be bound by the registration
provisions of this Agreement. 
  
 12. Reports Under The 1934
Act. 
  
 With a view to making available to the Holders the
benefits of Rule 144 promulgated under the Securities Act or any other similar rule or regulation of the SEC that may at any time permit the Holders to sell securities of the Company to the public without registration (“Rule 144”),
the Company agrees to: 
  
 (a) make and keep public information
available, as those terms are understood and defined in Rule 144; 
  
 (b) file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the 1934 Act so long as the Company remains subject to such requirements and the filing of such reports and other
documents is required for the applicable provisions of Rule 144; and 
  
 (c) furnish to each Holder so long as such Holder owns Registrable Securities, promptly upon request, (i) a written statement by the Company, if true, that it has complied with the reporting requirements of Rule 144, the Securities Act and
the 1934 Act, (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested to permit the Holders to sell such
securities pursuant to Rule 144 without registration. 
  
 13.
Miscellaneous. 
  
 (a) Remedies. The Company and
the Purchasers acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that
the parties shall be entitled to an injunction or injunctions 

			
	 Star Scientific, Inc.
	 	Page 15

  

 to prevent or cure breaches of the provisions of this Agreement and to enforce specifically the terms and provisions
hereof, this being in addition to any other remedy to which any of them may be entitled by law or equity. 
  
 (b) Jurisdiction. Each of the Company and each Purchaser (i) hereby irrevocably submits to the exclusive jurisdiction of the United States
District Court, the New York State courts and other courts of the United States sitting in the Borough of Manhattan, New York County, New York State for the purposes of any suit, action or proceeding arising out of or relating to this Agreement and
(ii) hereby waives, and agrees not to assert in any such suit action or proceeding, any claim that it is not personally subject to the jurisdiction of such court, that the suit, action or proceeding is brought in an inconvenient forum or that the
venue of the suit, action or proceeding is improper. The Company and each Purchaser consent to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing in this paragraph shall affect or limit any right to serve process in any other manner permitted by law. 
  
 (c) Notices. Any notice or other communication required or permitted
to be given hereunder shall be in writing by facsimile, mail or personal delivery and shall be effective upon actual receipt of such notice. The addresses for such communications shall be: 
  
 to the Company: 
  

			
	 Star Scientific, Inc.

	 801 Liberty Way

	 Chester, Virginia 23836

	 Telephone:
	 	 (804) 530-0535

	 Facsimile:
	 	 (804) 530-8474

	 Attention:
	 	 Christopher G. Miller

  
 with a copy to:

  

			
	 Star Scientific, Inc.

	 7475 Wisconsin Ave.

	 Suite 850

	 Bethesda, MD 20814

	 Telephone:
	 	 (301) 654-8300

	 Facsimile:
	 	 (301) 654-9308

	 Attention:
	 	 Robert Pokusa, Esq.

  
 to the Purchasers:

  

			
	As set forth on Schedule I hereto

  
 Any party hereto may from time to time
change its address for notices by giving at least five days’ written notice of such changed address to the other parties hereto. 

			
	 Star Scientific, Inc.
	 	Page 16

  

 (d) Waivers. No waiver by any party of any default with respect to any provision, condition or
requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right accruing to it thereafter. 
  
 (e) Execution in Counterpart. This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same agreement, it being understood that all parties need not sign the same counterpart.

  
 (f) Signatures. Facsimile signatures shall be valid
and binding on each party submitting the same. 
  
 (g) Entire
Agreement; Amendment. This Agreement, together with the Purchase Agreement and the agreements and documents contemplated hereby and thereby, contains the entire understanding and agreement of the parties. 
  
 (h) Governing Law. This Agreement and the validity and performance of
the terms hereof shall be governed by and construed in accordance with the laws of the State of New York applicable to contracts executed and to be performed entirely within such state. 
  
 (i) Jury Trial. EACH PARTY HERETO WAIVES THE RIGHT TO A TRIAL BY JURY. 
  
 (j) Titles. The titles used in this Agreement are used for
convenience only and are not to be considered in construing or interpreting this Agreement. 
  
 (k) No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rule of strict construction will be applied against
any party. 
  
 [Signature Page Follows] 

			
	 Star Scientific, Inc.
	 	Page 17

  

 In Witness Whereof, the parties hereto have caused this Agreement to be duly executed as of the
date first above written. 
  

			
	 STAR SCIENTIFIC, INC.

		
	 By:
	 	 /s/  Paul L. Perito

	 Name:
	 	 Paul L. Perito

	 Title:
	 	 Chairman, President & C.O.O.

	
	 PORTSIDE GROWTH & OPPORTUNITY FUND

		
	 By:
	 	 /s/  Jeffrey Smith

	 Name:
	 	Jeffrey Smith
	 Title:
	 	 Authorized Signatory

 Schedule I 
  

			
	 Name of Purchaser

	 	 Contact Information

	 Portside Growth & Opportunity Fund
	 	 c/o Ramius Capital Group
 666 3rd Avenue, 26th Floor
 New York, New York 10017
 (212) 845-7955
 (212) 845-7999
 Attention: Jeff SmithExhibit 10.5

 SECOND RESTATED NON-CIRCUMVENTION AND FINDER’S FEE AGREEMENT 
  
 This Second Restated Non-Circumvention and Finder’s Fee Agreement (this
“Agreement”) is made and entered into as of this 15 day of April, 2004 by and between STAR SCIENTIFIC, INC. (the “Company”) and REEDLAND CAPITAL PARTNERS (“Reedland”), an Institutional Division Of Financial West
Group, broker-dealer and member NASD/SIPC/MSRB. 
  
 W I T N E
S S E T H 
  
 WHEREAS, pursuant to that certain Restated Non-Circumvention
and Finder’s Fee Agreement entered into by and between the Company and Reedland effective as of March 23, 2004 (the “March 23rd Agreement”) Reedland introduced to the Company ELLIOTT CAPITAL ADVISORS, L.P. (collectively with its affiliated funds and other investors as identified on Exhibit “A” the “Investors”) for the
purpose of evaluating a potential investment in the Company and/or the Company’s subsidiaries by Elliott; and 
  
 WHEREAS, on March 25, 2004, Elliott purchased $9,000,000 of the Company’s 8% Senior Convertible Debentures from the Company, and Reedland was compensated by the
Company in connection therewith in accordance with the terms of the March 23rd Agreement; and 
  
 WHEREAS, the Investors have expressed an interest to Reedland and/or the Company in making an
additional investment in the Company in the amount of $4,000,000 and an option for an additional $4,000,000 (the “Follow-On Investment”); and 
  
 WHEREAS, the Company has agreed, for itself, and on behalf of its directors, officers, employees, agents, advisors, affiliates or their respective representatives, to
compensate Reedland in the event that the Investor and the Company consummate and close the Follow-On Investment, upon the terms and conditions set forth herein; 
  
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and intending to be legally bound, the parties hereto agree as
follows: 
  
 1    Reedland will not make any representation to
the Investors regarding the Company or enter into any covenants or agreements with the Investors on behalf of the Company. The Company has the exclusive right, in its sole discretion, to accept or reject any proposal from the Investors. 

 
 2    Non-Circumvention. In the event that the Investors
purchase the Company’s securities through the Follow-On Investment directly from the Company, including shares of the Company’s common stock (the “Common Stock” or “Common Shares”), convertible preferred stock,
warrants, and/or other securities (including any convertible debt instruments) convertible into or exercisable for Common Shares (collectively, the “Securities”), the Company agrees that it will not circumvent Reedland and shall compensate
Reedland in connection therewith as set forth below: 
  
 a.
Cash Commission. Upon the closing of the Follow-On Investment by the Investors (the “Closing Date”), the Company agrees to pay Reedland a cash commission of Two Hundred Eighty Thousand Dollars ($280,000), payable by wire transfer.

  
 3    Non-Exclusive Agreement/Fees Not Applicable to
Public Offerings. Notwithstanding the foregoing or anything to the contrary stated herein, the Company and Reedland agree that this Agreement shall be exclusive only to the Investors with respect to the Follow-On Investment and otherwise shall
not prohibit the Company from entering into any other stock purchase agreement with parties other than the Investors, nor shall this Agreement prohibit the Company from entering into any investment banking relationship, merger agreement, or
underwriting agreement or other transaction with any other party. In addition, no fees or compensation of any nature whatsoever shall be due or payable by the Company to Reedland in the event that the Investors purchases the Company’s equity
securities pursuant to a firm underwritten public offering by the Company or outside of the Follow-On Investment. 

			
	Star Scientific, Inc.	 	 
	Second Restated Non-Circumvention and Finders Fee Agreement	 	Page 2

  
 4    Offering
Materials/No General Solicitation. Reedland has not and will not use any offering materials or other information and data regarding the Company other than the Company’s publicly filed reports and only such other materials as the Company
will have approved in writing prior to their use, nor shall Reedland do any advertising or make any general solicitation on behalf of the Company in connection with the offering of the Securities to the Investors by the Company. 
  
 5    Press Release/SEC Filings. The Company agrees that any
reference to Reedland in any press release, SEC filings, or other communications issued by the Company (if any) will refer to Reedland as “Reedland Capital Partners, an Institutional Division of Financial West Group”. 
  
 6    Term. The term of this Agreement shall be deemed to have
commenced on February 20, 2004 and shall continue in effect for a period of one (1) year. 
  
 7    Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California, and any disputes arising hereunder will be adjudicated in
federal and state court situated therein. The Company hereby irrevocably agrees to submit to such venue in California and to the personal and subject matter jurisdiction of said courts. To the extent any dispute arises between the parties hereto
regarding any of the subject matter hereof, the prevailing party in any action or proceeding brought in connection therewith will be entitled to reasonable attorneys’ fees and court costs from the losing party. 
  
 8    Entire Agreement. This is the entire agreement between the
parties and supersedes all prior negotiations or agreements. Any modifications to this Agreement must be made in writing and signed by the parties. 
  
 9    Indemnification. The Company shall indemnify and hold harmless Reedland and its officers, directors, agents and employees from any loss,
damage or liability resulting from Company’s violation of the terms of this Agreement or any agreement between the Company and the Elliott Investors regarding the offering and/or sale of the Company’s Securities. If Reedland becomes
entitled to compensation hereunder, it agrees to indemnify the Company and hold it harmless from and against any claim by any other person or finder seeking finder’s fees or similar compensation for services rendered with respect a transaction
with the Investors, where such person acted in concert with Reedland. Such indemnification provisions shall survive the consummation, cancellation, or abandonment of the proposed transaction. 
  
 10    Confidentiality. Throughout the term of this Agreement and
following termination hereof for any reason, Reedland agrees to hold inviolate and keep secret all non-public knowledge or information processes, know-how, and other confidential information made known to it or otherwise acquired during the term of
this Agreement and will not disclose the same or anything related thereto to any other person, firm, bank, corporation, or other entity, or make use of such information for any purpose, except as may be required in the course and scope of performing
its obligations under this Agreement or as part of any mandated reporting required by law. 
  
 IN WITNESS WHEREOF, the undersigned have executed this Agreement on the date and year first above written. 
  

									
	 REEDLAND CAPITAL PARTNERS
 An Institutional
Division of Financial West Group
	 	 	 	 STAR SCIENTIFIC, INC.

					
	By:	 	/s/  Thomas J. Griesel	 	 	 	By:	 	/s/  Jonnie Williams
	 	 	
	 	 	 	 	 	

	 	 	 Thomas J. Griesel
 Senior Vice President
 30 Sunnyside Avenue
 Mill Valley, CA 94941
	 	 	 	 	 	 Jonnie Williams
 Chief Executive Officer
 801 Liberty Way
 Chester VA, 23836

			
	Star Scientific, Inc.	 	 
	Second Restated Non-Circumvention and Finders Fee Agreement	 	Page 3

  
  
 Exhibit “A” 
  
 Elliott Capital Advisors affiliated funds 
  
 1.  Elliott Associates, L.P. 
 2.  Elliott International, L.P. 
 3.  Portside Growth & Opportunity Fund

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}]]